Model-based analyses built on burden-of-disease and cost–effectiveness theory predict that pharmaceutical interventions may efficiently mitigate both the epidemiologic and economic impact of an influenza pandemic. Pharmaceutical interventions typically encompass the application of (pre)pandemic influenza vaccines, other vaccines (notably pneumococcal), antiviral treatments and other drug treatment (e.g., antibiotics to target potential complications of influenza). However, these models may be too limited to capture the full macro-economic impact of pandemic influenza. The aim of this article is to summarize current health-economic modeling approaches to recognize the strengths and weaknesses of these approaches, and to compare these with more recently proposed alternative methods. We conclude that it is useful, particularly for policy and planning purposes, to extend modeling concepts through the application of alternative approaches, including insurers’ risk theories, human capital approaches and sectoral and full macro-economic modeling.

Postma, M.J., Milne, G., Nelson, E.A.S., Pyenson, B., Basili, M., Coker, R., et al. (2010). Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, VIII, 1431-1439.

Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts

Basili, M.;
2010-01-01

Abstract

Model-based analyses built on burden-of-disease and cost–effectiveness theory predict that pharmaceutical interventions may efficiently mitigate both the epidemiologic and economic impact of an influenza pandemic. Pharmaceutical interventions typically encompass the application of (pre)pandemic influenza vaccines, other vaccines (notably pneumococcal), antiviral treatments and other drug treatment (e.g., antibiotics to target potential complications of influenza). However, these models may be too limited to capture the full macro-economic impact of pandemic influenza. The aim of this article is to summarize current health-economic modeling approaches to recognize the strengths and weaknesses of these approaches, and to compare these with more recently proposed alternative methods. We conclude that it is useful, particularly for policy and planning purposes, to extend modeling concepts through the application of alternative approaches, including insurers’ risk theories, human capital approaches and sectoral and full macro-economic modeling.
2010
Postma, M.J., Milne, G., Nelson, E.A.S., Pyenson, B., Basili, M., Coker, R., et al. (2010). Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, VIII, 1431-1439.
File in questo prodotto:
File Dimensione Formato  
articolo con epidemiologi.pdf

non disponibili

Descrizione: articolo principale
Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 151.5 kB
Formato Adobe PDF
151.5 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/21811
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo